Developmental and epileptic encephalopathies (DEEs) are a heterogeneous group of
disorders characterized by early-onset, often severe epileptic seizures and EEG …

The genetic basis of many epilepsies is increasingly understood, giving rise to the possibility
of precision treatments tailored to specific genetic etiologies. Despite this, current medical …

In the last 30 years, over 20 new anti-seizure medicines (ASMs) have been introduced into
the market for the treatment of epilepsy using well-established preclinical seizure and …

Introduction Modern drug discovery is generally accessed by useful information from
previous large databases or uncovering novel data. The lack of biological and/or chemical …

Over 30 antiseizure medicines (ASMs) have been uncovered in a diversity of preclinical
seizure and epilepsy models, with several critical inflection points in the 20th century …

Dravet syndrome (DS), an intractable childhood epileptic encephalopathy with a high fatality
rate, is typically caused by loss-of-function mutations in one allele of SCN1A, which encodes …

Epilepsy is a common brain disorder, characterized by spontaneous recurrent seizures, with
associated neuropsychiatric and cognitive comorbidities and increased mortality. Although …

Substantial efforts are underway toward optimizing the diagnosis, monitoring, and treatment
of seizures and epilepsy. We describe preclinical programs in place for screening …

Dravet syndrome is a severe genetic epilepsy primarily caused by de novo mutations in a
voltage-activated sodium channel gene (SCN1A). Patients face life-threatening seizures that …

Dravet syndrome is severe childhood-onset epilepsy, caused by loss of function mutations in
the SCN1A gene, encoding for the voltage-gated sodium channel NaV1. 1. The leading …